Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Free Cash Flow: 2016-2025

Historic Free Cash Flow for Collegium Pharmaceutical (COLL) over the last 10 years, with Sep 2025 value amounting to $78.2 million.

  • Collegium Pharmaceutical's Free Cash Flow rose 946.59% to $78.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $289.3 million, marking a year-over-year increase of 50.34%. This contributed to the annual value of $203.3 million for FY2024, which is 25.87% down from last year.
  • Collegium Pharmaceutical's Free Cash Flow amounted to $78.2 million in Q3 2025, which was up 8.12% from $72.4 million recorded in Q2 2025.
  • Over the past 5 years, Collegium Pharmaceutical's Free Cash Flow peaked at $99.7 million during Q2 2023, and registered a low of -$25.4 million during Q1 2022.
  • Over the past 3 years, Collegium Pharmaceutical's median Free Cash Flow value was $72.4 million (recorded in 2025), while the average stood at $62.1 million.
  • In the last 5 years, Collegium Pharmaceutical's Free Cash Flow plummeted by 226.22% in 2022 and then spiked by 946.59% in 2025.
  • Collegium Pharmaceutical's Free Cash Flow (Quarterly) stood at $35.7 million in 2021, then spiked by 83.24% to $65.4 million in 2022, then rose by 11.91% to $73.2 million in 2023, then rose by 14.90% to $84.1 million in 2024, then spiked by 946.59% to $78.2 million in 2025.
  • Its last three reported values are $78.2 million in Q3 2025, $72.4 million for Q2 2025, and $54.6 million during Q1 2025.